Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Identification of Novel and Known LDLR Variants Triggering Severe Familial Hypercholesterolemia in Saudi Families

Author(s): Fahad Alnouri*, Faisal A. Al-Allaf*, Mohammad Athar, Khalid Al-Rasadi, Dalal Alammari, Menwar Alanazi, Zainularifeen Abduljaleel, Zuhier Awan, Abdellatif Bouazzaoui, Ghida Dairi, Wafa M Elbjeirami, Hussam Karra, Abdulhalim J Kinsara and Mohiuddin M. Taher

Volume 20, Issue 4, 2022

Published on: 26 April, 2022

Page: [361 - 369] Pages: 9

DOI: 10.2174/1570161120666220304101606

Price: $65

Abstract

Background: Familial hypercholesterolemia (FH) is a common illness mainly caused by variants occurring in the low-density lipoprotein receptor (LDLR) gene. FH is a leading cause of coronary artery disease.

Objective: This study aims to determine genetic defect(s) in homozygous and heterozygous FH index patients and their first-degree blood relatives and understand the genotype-phenotype correlation.

Methods: This study employed the genetic screening of FH-related genes by next-generation sequencing and cascade screening by capillary sequencing.

Results: We identified the presence of a novel frameshift variant [c.335_336insCGAG, p.(F114Rfs*17)] and three known missense variants [c.622G>A, p.(E208K)], [c.1474G>A, p.(D492N)], [c.1429G>A, p.(D477N)] in the LDLR gene of four unrelated Saudi families with FH. In proband 1, a nonsense variant c.1421C>G, p.(S474*) was also detected at exon 9 of the lipoprotein lipase gene. The segregation arrangement of the identified variants corresponded with the clinical characteristics. In this study, all the detected variants were confined in the ligand-binding domain and epidermal growth factor (EGF)-precursor homology domain of the LDLR protein, which portrayed severe clinical phenotypes of FH. Moreover, these LDLR variants were in a highly conserved residue of the proteins.

Conclusion: In addition to the finding of the novel variant in the LDLR gene that extends the spectrum of variants causing FH, the results of this study also support the need for diagnostic screening and cascade genetic testing of this high-risk condition and to understand the genotype-phenotype correlation, which could lead to better prevention of coronary artery disease.

Keywords: Familial hypercholesterolemia, next-generation sequencing, variant, low-density lipoprotein receptor, cholesterol, coronary artery disease.

« Previous Next »
[1]
Al-Allaf FA, Coutelle C, Waddington SN, David AL, Harbottle R, Themis M. LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives. Int Arch Med 2010; 3(1): 36.
[http://dx.doi.org/10.1186/1755-7682-3-36] [PMID: 21144047]
[2]
Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124(1): 35-46.
[http://dx.doi.org/10.1016/j.cell.2005.12.022] [PMID: 16413480]
[3]
Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35(32): 2146-57.
[http://dx.doi.org/10.1093/eurheartj/ehu274] [PMID: 25053660]
[4]
Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 1990; 85(4): 1014-23.
[http://dx.doi.org/10.1172/JCI114531] [PMID: 2318961]
[5]
Landsberger D, Meiner V, Reshef A, et al. A nonsense mutation in the LDL receptor gene leads to familial hypercholesterolemia in the Druze sect. Am J Hum Genet 1992; 50(2): 427-33.
[PMID: 1734722]
[6]
Koivisto UM, Turtola H, Aalto-Setälä K, et al. The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland. J Clin Invest 1992; 90(1): 219-28.
[http://dx.doi.org/10.1172/JCI115839] [PMID: 1634609]
[7]
Al-Allaf FA, Athar M, Abduljaleel Z, et al. Identification of a novel nonsense variant c.1332dup, p.(D445*) in the LDLR gene that causes familial hypercholesterolemia. Hum Genome Var 2014; 1(1): 14021.
[http://dx.doi.org/10.1038/hgv.2014.21] [PMID: 27081511]
[8]
Al-Allaf FA, Athar M, Abduljaleel Z, et al. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease. Gene 2015; 565(1): 76-84.
[http://dx.doi.org/10.1016/j.gene.2015.03.064] [PMID: 25839937]
[9]
Al-Allaf FA, Alashwal A, Abduljaleel Z, et al. Identification of a recurrent frameshift mutation at the LDLR exon 14 (c.2027delG, p.(G676Afs*33)) causing familial hypercholesterolemia in Saudi Arab homozygous children. Genomics 2016; 107(1): 24-32.
[http://dx.doi.org/10.1016/j.ygeno.2015.12.001] [PMID: 26688439]
[10]
Al-Allaf FA, Alashwal A, Abduljaleel Z, et al. Compound heterozygous LDLR variant in severely affected familial hypercholesterolemia patient. Acta Biochim Pol 2017; 64(1): 75-9. a
[PMID: 27878139]
[11]
Alallaf FH, Nazar FA, Alnefaie M, et al. The spectrum of familial hypercholesterolemia (FH) in Saudi Arabia: Prime time for patient FH registry. Open Cardiovasc Med J 2017; 11: 66-75. b
[http://dx.doi.org/10.2174/1874192401711010066] [PMID: 28868092]
[12]
Morad FA, Rashidi OM, Sadath SS, et al. In silico approach to investigate the structural and functional attributes of familial hypercholesterolemia variants reported in the saudi population. J Comput Biol 2018; 25(2): 170-81.
[http://dx.doi.org/10.1089/cmb.2017.0018] [PMID: 29172679]
[13]
Alnouri F, Athar M, Al-Allaf FA, et al. Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia. Atherosclerosis 2018; 277: 425-33.
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.06.878] [PMID: 30270081]
[14]
Alharbi KK, Kashour TS, Al-Hussaini W, et al. Screening for genetic mutations in LDLR gene with familial hypercholesterolemia patients in the Saudi population. Acta Biochim Pol 2015; 62(3): 559-62.
[http://dx.doi.org/10.18388/abp.2015_1015] [PMID: 26345093]
[15]
Al-Ashwal A, Alnouri F, Sabbour H, et al. Identification and treatment of patients with homozygous familial hypercholesterolaemia: Information and recommendations from a Middle East advisory panel. Curr Vasc Pharmacol 2015; 13(6): 759-70.
[http://dx.doi.org/10.2174/1570161113666150827125040] [PMID: 26311574]
[16]
Al-Rasadi K, Alhabib KF, Al-Allaf F, et al. The gulf familial hypercholesterolemia registry (Gulf FH): Design, rationale and preliminary results. Curr Vasc Pharmacol 2020; 18(1): 57-64.
[http://dx.doi.org/10.2174/1570161116666181005125459] [PMID: 30289081]
[17]
El-Mouzan MI, Al-Salloum AA, Al-Herbish AS, Qurachi MM, Al-Omar AA. Regional variations in the prevalence of consanguinity in Saudi Arabia. Saudi Med J 2007; 28(12): 1881-4.
[PMID: 18060221]
[18]
Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. Reprod Health 2009; 6(1): 17.
[http://dx.doi.org/10.1186/1742-4755-6-17] [PMID: 19811666]
[19]
Batais MA, Almigbal TH, Bin Abdulhak AA, Altaradi HB, AlHabib KF. Assessment of physicians’ awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: Is there a gap? PLoS One 2017; 12(8): e0183494.
[http://dx.doi.org/10.1371/journal.pone.0183494] [PMID: 28817709]
[20]
Robinson JG, Goldberg AC. National lipid association expert panel on familial hypercholesterolemia. treatment of adults with familial hypercholesterolemia and evidence for treatment: Recommendations from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol 2011; 5(3) (Suppl.): S18-29.
[http://dx.doi.org/10.1016/j.jacl.2011.03.451] [PMID: 21600526]
[21]
Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1(6): 445-66.
[http://dx.doi.org/10.1002/humu.1380010602] [PMID: 1301956]
[22]
Yang K-C, Su Y-N, Shew J-Y, et al. LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population. J Formos Med Assoc 2007; 106(10): 799-807.
[http://dx.doi.org/10.1016/S0929-6646(08)60044-3] [PMID: 17964958]
[23]
Abifadel M, Varret M, Rabès J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34(2): 154-6.
[http://dx.doi.org/10.1038/ng1161] [PMID: 12730697]
[24]
Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004; 114(4): 349-53.
[http://dx.doi.org/10.1007/s00439-003-1071-9] [PMID: 14727179]
[25]
Zambon A, Torres A, Bijvoet S, et al. Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency. Lancet 1993; 341(8853): 1119-21.
[http://dx.doi.org/10.1016/0140-6736(93)93129-O] [PMID: 8097805]
[26]
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4(7): 1073-81.
[http://dx.doi.org/10.1038/nprot.2009.86] [PMID: 19561590]
[27]
Edrees BM, Athar M, Al-Allaf FA, et al. Next-generation sequencing for molecular diagnosis of autosomal recessive polycystic kidney disease. Gene 2016; 591(1): 214-26.
[http://dx.doi.org/10.1016/j.gene.2016.07.021] [PMID: 27401137]
[28]
Garcia-Rios A, Delgado-Lista J, Perez-Martinez P, et al. Genetic variations at the lipoprotein lipase gene influence plasma lipid concentrations and interact with plasma n-6 polyunsaturated fatty acids to modulate lipid metabolism. Atherosclerosis 2011; 218(2): 416-22.
[http://dx.doi.org/10.1016/j.atherosclerosis.2011.07.092] [PMID: 21840003]
[29]
Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Hypercholesterolemia: The role of PCSK9. Arch Biochem Biophys 2017; 625-626: 39-53.
[http://dx.doi.org/10.1016/j.abb.2017.06.001] [PMID: 28587771]
[30]
Alnouri F, Al-Allaf FA, Athar M, et al. Xanthomas can be misdiagnosed and mistreated in homozygous familial hypercholesterolemia patients: A call for increased awareness among dermatologists and health care practitioners. Glob Heart 2020; 15(1): 19.
[http://dx.doi.org/10.5334/gh.759] [PMID: 32489792]
[31]
Leren TP, Berge KE. Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated. PLoS One 2011; 6(2): e16721.
[http://dx.doi.org/10.1371/journal.pone.0016721] [PMID: 21364743]
[32]
Wiegman A, Gidding SS, Watts GF, et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425-37.
[http://dx.doi.org/10.1093/eurheartj/ehv157] [PMID: 26009596]
[33]
Wang H, Xu S, Sun L, Pan X, Yang S, Wang L. Functional characterization of two low-density lipoprotein receptor gene mutations in two Chinese patients with familial hypercholesterolemia. PLoS One 2014; 9(3): e92703.
[http://dx.doi.org/10.1371/journal.pone.0092703] [PMID: 24671153]

Rights & Permissions Print Cite
Article Metrics
11
© 2024 Bentham Science Publishers | Privacy Policy